image credit: Freepik

BioNTech and Autolus enter CAR-T cell therapy collaboration worth over $250m

February 13, 2024


Both companies have entered into a license and option agreement, as well as a securities purchase agreement, in connection with the collaboration.

Under the terms of the agreement, BioNTech will purchase $200m of Autolus’ US depositary shares in a private placement and will make a cash payment of $50m.

In exchange, BioNTech will be eligible to receive an up to mid-single-digit royalty of its autologous CD19 CAR T cell therapy, obe-cel, net sales, while Autolus retains full rights to the development and commercialisation of obe-cel.

Read More on PMLiVE